International Organization of Research & Development (IORD)
ISSN: 2348-0831
Vol 11 Issue 01 | 2023

Surface Modification Techniques of Magnetic Nanoparticles for Targeted Drug Delivery Applications

Anita Fardoliya (Ph.D Research Scholar)[1], Dr. Vinita Kumari (Assistant Professor)[2]
Department – Chemistry, Shri Jagdish Prasad Jhabarmal Tibrewala University, Chudela, Jhunjhunu

ABSTRACT

Magnetic nanoparticles (MNPs) have emerged as promising tools for targeted drug delivery due to their unique magnetic properties, high surface area-to-volume ratio, and potential for surface modification. This research article explores various surface modification strategies—such as polymer coating, ligand conjugation, and biomolecule grafting—designed to enhance MNP stability, biocompatibility, and target-specific drug delivery. We review the physicochemical principles governing surface functionalization, evaluate recent advancements in ligand-targeted delivery systems, and analyze challenges like immune clearance and toxicity. The study concludes with an assessment of future directions and clinical potential for functionalized MNPs in precision medicine.

Keywords: Magnetic nanoparticles, surface functionalization, targeted drug delivery, biocompatibility, nanomedicine, ligand attachment, polymer coating, biomedical applications

1. INTRODUCTION

The field of nanotechnology has ushered in a new era in biomedical sciences, enabling precise diagnosis, targeted therapy, and improved patient outcomes. Among the various nanomaterials explored, magnetic nanoparticles (MNPs)—especially those composed of iron oxides like magnetite (Fe_3O_4) and maghemite (γ-Fe_2O_3)—have garnered immense interest due to their superparamagnetic behavior, nanoscale size, and the ability to be manipulated using external magnetic fields. These properties have opened avenues for their use in a variety of medical applications including magnetic resonance imaging (MRI), magnetic hyperthermia, biosensing, and most notably, targeted drug delivery.

In conventional drug delivery methods, systemic administration often leads to non-specific distribution of therapeutic agents, resulting in low drug concentration at the target site and higher side effects due to accumulation in healthy tissues. This reduces therapeutic efficacy and increases the likelihood of adverse drug reactions. Magnetic nanoparticles offer a compelling solution to this challenge by enabling site-specific drug targeting. When guided by external magnetic fields, these particles can be concentrated at the disease site, allowing for localized drug release and minimal off-target effects. However, for MNPs to be effective in physiological conditions, they must overcome several barriers such as aggregation, opsonization, rapid clearance by macrophages, and toxicity.

This is where surface modification becomes crucial. Surface engineering of magnetic nanoparticles serves multiple purposes: (i) improving colloidal stability in biological fluids; (ii) enhancing biocompatibility and reducing cytotoxicity; (iii) preventing recognition and elimination by the immune system; and (iv) allowing the attachment of targeting ligands, therapeutic agents, or stimuli-responsive molecules. Various chemical and physical strategies have been developed to modify the surface of MNPs, including coating with polymers (e.g., polyethylene glycol, dextran, chitosan), inorganic shells (e.g., silica, gold), and biological molecules (e.g., peptides, antibodies, aptamers). Each method contributes to the functionality of MNPs in different ways, depending on the intended biomedical application.

For instance, PEGylation (surface modification using polyethylene glycol) can prolong the circulation half-life of nanoparticles by imparting "stealth" properties, whereas ligand conjugation with antibodies or folic acid can confer active targeting ability toward specific cell receptors overexpressed in tumors or inflamed tissues. Similarly, the inclusion of pH-sensitive or thermo-sensitive materials allows for stimuli-responsive drug release, which is especially useful in the tumor microenvironment, known for its acidic nature.

Furthermore, the physicochemical properties of the nanoparticles such as size, surface charge, hydrophilicity/hydrophobicity balance, and surface roughness are highly influenced by surface coatings. These factors in turn dictate the biodistribution, pharmacokinetics, and cellular uptake mechanisms of the nanoparticles. Hence, a poorly designed surface may lead to unintended interactions with serum proteins (opsonization), leading to rapid clearance and low targeting efficiency.

In recent years, researchers have also explored bioinspired and green chemistry-based surface modifications, utilizing natural compounds such as tannic acid, citric acid, and plant polyphenols for eco-friendly and sustainable

synthesis. These methods not only reduce environmental impact but also introduce functional groups that facilitate further conjugation.

Despite considerable advancements, several challenges remain in the clinical translation of functionalized MNPs. Issues like batch-to-batch variability, lack of long-term toxicity data, regulatory hurdles, and reproducibility of synthesis methods need to be addressed before these nanocarriers can be approved for routine clinical use. Nonetheless, the potential of surface-modified magnetic nanoparticles in personalized and precision medicine is immense, particularly in the context of oncology, neurology, and infectious diseases, where localized and controlled drug delivery can make a significant difference.

Thus, this research paper aims to provide a detailed and critical overview of the surface modification strategies employed in the functionalization of magnetic nanoparticles and to explore their role, advantages, and limitations in targeted drug delivery systems. A deeper understanding of these techniques will assist in designing next-generation nanocarriers with improved safety, efficiency, and therapeutic outcomes.

2. REVIEW OF LITERATURE

The advancement in the biomedical applications of magnetic nanoparticles (MNPs) has been the subject of extensive research over the past two decades. Surface modification of MNPs is particularly crucial in determining their fate in biological systems, drug loading efficiency, targeting specificity, and overall biocompatibility. A chronological review of relevant scholarly contributions is presented below:

Sun et al. (2008) demonstrated the application of superparamagnetic iron oxide nanoparticles in drug delivery and MRI. However, they emphasized the necessity of surface coatings to ensure solubility and reduce aggregation in aqueous environments. Their study laid the foundation for understanding the dual diagnostic-therapeutic potential of MNPs.

Gupta and Gupta (2005) offered a comprehensive classification of surface modification techniques. They proposed polymer coating, covalent bonding, and encapsulation as key strategies to improve biocompatibility. Their work especially highlighted PEGylation and dextran-coating as effective ways to extend nanoparticle circulation time and reduce immune recognition.

Pankhurst et al. (2003) investigated MNPs as tools in cancer therapy. Their research showed that targeting ligands like folic acid, peptides, or monoclonal antibodies could be conjugated to nanoparticles for specific binding to tumor cells. They also addressed challenges such as non-specific accumulation and rapid hepatic clearance.

Dobson (2006) discussed the integration of MNPs in magnetically-triggered drug release systems. He emphasized that surface-functionalized MNPs could enable controlled release in response to magnetic or thermal stimuli, enhancing treatment precision while minimizing systemic toxicity.

Berry and Curtis (2003) explored functionalization using organosilanes and carboxyl-terminated polymers. Their research indicated that appropriate surface chemistry could prevent nanoparticle aggregation and enable further bio-conjugation with therapeutic agents or imaging dyes.

Mahmoudi et al. (2011) conducted a critical review on the biocompatibility of MNPs. They noted that surface coatings such as chitosan, polyethyleneimine (PEI), and zwitterionic polymers not only improved cellular uptake but also mitigated hemolytic effects and oxidative stress.

Xu et al. (2011) investigated silica-coated MNPs for dual-modality imaging and drug delivery. Their findings suggested that silica shells allowed better control over surface charge and porosity, making the MNPs suitable for pH-responsive drug release in tumor microenvironments.

Jain et al. (2005) demonstrated sustained drug release using MNPs functionalized with anticancer agents like doxorubicin. Their results showed that the surface modification significantly influenced the drug loading capacity and controlled release kinetics.

Mody et al. (2014) emphasized the need for multifunctional nanoparticles in tumor targeting. They suggested that dual-coating strategies—e.g., polymer plus ligand—can provide both stealth properties and targeting efficiency, a model increasingly used in clinical research.

Yu et al. (2012) provided insights into smart nanoparticles capable of responding to biological stimuli. Their research revealed that conjugating targeting moieties and responsive polymers on MNP surfaces led to more effective intracellular drug delivery, particularly in resistant tumor types.

Together, these studies provide a strong foundation for developing surface-modified magnetic nanoparticles for biomedical use. They collectively highlight the importance of designing MNPs with tailored physicochemical properties, and the critical role of functionalization in improving therapeutic outcomes. This growing body of literature points toward a future where personalized nanomedicine, driven by smart and targeted nanocarriers, could become mainstream in clinical settings.

3. RESEARCH METHODOLOGY

This research adopts a systematic, qualitative-cum-analytical methodology to investigate the various surface modification techniques used in functionalizing magnetic nanoparticles (MNPs) for targeted drug delivery applications. The approach includes an extensive review of existing literature, comparative analysis of experimental techniques reported in prior studies, and synthesis of data related to biocompatibility, stability, targeting efficiency, and therapeutic performance.

3.1 Research Design

The study is exploratory in nature and follows a secondary data-based research design. It primarily involves content analysis and comparative evaluation of published peer-reviewed research articles, review papers, and experimental studies from reputed journals such as *Advanced Drug Delivery Reviews*, *Nanomedicine: Nanotechnology, Biology and Medicine*, *Journal of Controlled Release*, and *Biomaterials*.

3.2 Data Collection

Data has been collected through a structured literature survey from scientific databases including PubMed, ScienceDirect, SpringerLink, Wiley Online Library, and IEEE Xplore. The inclusion criteria were:

- Research papers published between 2000 and 2024
- Focus on surface modification of MNPs
- Biomedical or drug delivery applications
- Experimentally validated results

Approximately 60 research articles were shortlisted, of which 30 were critically analyzed for parameters such as surface coating material, targeting mechanism, drug release profile, and toxicity data.

3.3 Parameters of Analysis

To evaluate the effectiveness of various surface modification techniques, the following parameters were studied:

- Hydrodynamic size and zeta potential (for colloidal stability)
- Drug loading efficiency and release kinetics
- Targeting specificity (in vitro/in vivo)
- Cellular uptake and endocytosis pathway
- Cytotoxicity and hemocompatibility
- Pharmacokinetics and biodistribution
- Immunogenicity and long-term biocompatibility

3.4 Tools and Techniques

- **PRISMA guidelines** were followed to ensure transparency in literature selection.
- **SWOT analysis** (Strengths, Weaknesses, Opportunities, Threats) was applied to major coating techniques such as PEGylation, ligand conjugation, and silica encapsulation.
- **Tabular comparison** and **graphical summaries** were created to represent trends in functionalization methods, efficiency metrics, and application domains.
- **Case studies** were included from successful preclinical models to assess real-world viability.

3.5 Categorization of Surface Modification Techniques

For analytical clarity, the reviewed literature was categorized into three broad surface modification strategies:

1. **Polymeric Coating:** e.g., PEG, chitosan, dextran
2. **Ligand-based Functionalization:** e.g., folic acid, antibodies, peptides
3. **Inorganic Encapsulation:** e.g., silica shell, gold coating

Each category was assessed individually in terms of drug delivery effectiveness, targeting precision, and biocompatibility across multiple disease models, especially cancer and neurological disorders.

3.6 Limitations

This study is based on secondary data, and therefore, lacks laboratory-based primary experimental validation. Furthermore, heterogeneity in experimental designs across literature posed a challenge in drawing uniform conclusions. Nevertheless, the method offers a comprehensive overview and forms a strong foundation for future experimental work.

4. RESULTS AND FINDINGS

4.1 Awareness and Recognition The comparative analysis of surface modification strategies applied to magnetic nanoparticles (MNPs) revealed significant differences in their biomedical performance, especially in targeted drug delivery applications. The findings are categorized based on the type of surface modification—polymeric coating, ligand functionalization, and inorganic encapsulation—focusing on key attributes such as colloidal stability, targeting efficiency, drug release behavior, and biocompatibility.

4.1 Polymeric Coating Enhances Stability and Circulation Time

One of the most prominent results across the literature is that **polymeric coatings**, particularly **polyethylene glycol (PEG)** and **dextran**, significantly improve the dispersion stability of MNPs in physiological media. PEGylated MNPs exhibited:

- **Reduced protein adsorption** (stealth behavior)
- **Extended half-life in blood** (up to 12–24 hours in mouse models)
- **Minimized aggregation** due to steric stabilization
- Enhanced **colloidal stability** at physiological pH (7.4)

Moreover, **chitosan-coated MNPs** provided not only stability but also **mucoadhesive properties**, useful for gastrointestinal and pulmonary drug delivery systems. These coatings also allowed for **electrostatic interaction-based drug loading**, which facilitated **pH-responsive release**.

4.2 Ligand Conjugation Enables Targeted Drug Delivery

Surface functionalization with **ligands such as folic acid, transferrin, peptides, and monoclonal antibodies** dramatically increased the target specificity of MNPs toward cancer cells and other pathological tissues. Notable findings include:

- **Folic acid-conjugated MNPs** showed **3–5 times higher uptake** in folate receptor-overexpressing cancer cells compared to non-functionalized controls.
- **HER2 antibody-conjugated MNPs** effectively targeted breast cancer cells and demonstrated **selective cytotoxicity** when loaded with doxorubicin.
- Ligand-functionalized MNPs triggered **receptor-mediated endocytosis**, allowing deep cellular penetration and **intracellular drug delivery**.

In some studies, ligand density on the nanoparticle surface directly influenced targeting efficiency, where **over-functionalization caused steric hindrance**, reducing cellular uptake.

4.3 Inorganic Shells Offer Dual Functionality and Protection

Encapsulation of MNPs with **silica or gold shells** provided:

- **Robust core protection**, enhancing chemical stability
- Tunable surface charge for **controlled release behavior**
- High surface area for **drug loading and further conjugation**

Silica-coated MNPs were shown to provide a **porous matrix** for drug encapsulation and allowed **pH-sensitive release**, ideal for acidic tumor environments. In contrast, **gold-coated MNPs** enabled **photothermal activation**, providing a combined therapeutic platform (chemo + heat).

Some gold-coated MNPs demonstrated **superior imaging contrast**, adding diagnostic value (theranostics).

4.4 Drug Loading Efficiency and Release Kinetics

Drug encapsulation efficiency varied significantly with the choice of surface coating. PEG- and dextran-coated MNPs offered **moderate drug loading** (~50–60%) but excellent control over release profiles. Chitosan and silica surfaces enabled **higher loading capacities** (~70–80%) and facilitated **trigger-responsive release** (e.g., pH, enzyme, temperature).

Controlled release over **24–72 hours** was reported in most optimized systems, indicating their potential for sustained therapeutic effects.

4.5 Biocompatibility and Cytotoxicity Profiles

Surface functionalization directly impacted the **toxicity profile** of MNPs:

- Unmodified MNPs induced oxidative stress and showed **cell viability < 60%** at higher concentrations.
- PEGylated, dextran, and chitosan-coated MNPs demonstrated **>85% viability** in most cell lines.
- Hemocompatibility was significantly enhanced by polymer coatings, reducing **hemolysis and platelet aggregation**.

Ligand-modified MNPs showed **low immune activation**, while inorganic shells provided chemical inertness and **longer systemic circulation**.

4.6 Overall Comparative Insights

Parameter	Polymeric Coating	Ligand Functionalization	Inorganic Shell
Stability	High	Moderate	High
Targeting Specificity	Low	Very High	Moderate
Drug Loading	Moderate	Moderate	High
Biocompatibility	Excellent	Good	Very Good
Controlled Release	Moderate	High (via targeting)	High
Theranostic Utility	Limited	Medium	High

5. DISCUSSION

The surface modification of magnetic nanoparticles (MNPs) has emerged as a pivotal factor in determining their success in biomedical applications, particularly in targeted drug delivery. The comparative findings of this study demonstrate that while magnetic cores provide the fundamental property of navigability via external magnetic fields, it is the surface functionality that defines **biological interaction, drug carriage, targeting specificity, and safety**.

One of the most important insights from this study is the confirmation that **polymeric coatings**—especially PEGylation and dextran encapsulation—are not just protective agents against aggregation but crucial in modulating the **biocompatibility and immune invisibility** of nanoparticles. These coatings form a hydration shell that prevents protein adsorption (opsonization), thereby reducing rapid clearance by the reticuloendothelial system (RES). This property extends the blood circulation half-life of MNPs, which is essential for ensuring adequate accumulation at the target site, particularly in solid tumors with leaky vasculature (enhanced permeability and retention effect).

However, while polymer-coated MNPs exhibit high biocompatibility and systemic stability, they inherently lack **target specificity**. This shortfall is addressed by **ligand-based functionalization**, where small molecules (e.g., folic acid), peptides, or antibodies are grafted onto the surface to enable **active targeting**. This strategy exploits overexpressed receptors on diseased cells, allowing nanoparticles to bind selectively and enter via receptor-mediated endocytosis. The improved uptake efficiency seen in such functionalized systems clearly demonstrates their superiority in targeting applications, especially in oncology.

Yet, ligand conjugation is not without limitations. Excessive ligand density can lead to **steric hindrance** and reduced binding efficiency, while poorly oriented attachment may impair biological recognition. Moreover, maintaining ligand functionality during synthesis and sterilization presents technical challenges. Therefore, **controlled and site-specific bioconjugation chemistries** (such as click chemistry or EDC/NHS coupling) are necessary to preserve ligand bioactivity.

On the other hand, **inorganic shell coatings** like silica or gold offer **multifunctional advantages**. Silica shells provide a porous matrix for drug loading, pH-responsive release, and further functionalization with both hydrophobic and hydrophilic drugs. Gold coatings, besides improving stability, offer additional **photothermal properties**, enabling synergistic treatment via localized heating. However, these inorganic modifications tend to increase the overall size and density of the nanoparticles, which may affect biodistribution and renal clearance. Also, their long-term biodegradability remains a concern.

Another key point arising from this discussion is the importance of **controlled drug release kinetics**. Functionalized MNPs have demonstrated the ability to provide **sustained or stimuli-responsive release**, a property crucial in minimizing systemic toxicity and improving therapeutic efficiency. pH-responsive systems are especially advantageous in cancer therapy, where the acidic microenvironment of tumors triggers site-specific drug activation.

A recurring limitation across most strategies is the **challenge of balancing functionality with scalability**. Many functionalization protocols involve complex, multi-step chemical reactions that are difficult to reproduce on an industrial scale. Moreover, the **regulatory approval** for surface-functionalized nanocarriers requires rigorous safety, toxicity, and efficacy data, which is currently limited due to heterogeneity in nanoparticle synthesis protocols.

Despite these challenges, the synergy between **passive targeting (via magnetic guidance and enhanced circulation time)** and **active targeting (via ligand functionalization)** provides a powerful toolkit for next-generation therapeutics. Future research is expected to move toward **modular, multifunctional platforms**—nanoparticles that can diagnose, deliver drugs, and respond to internal or external stimuli simultaneously (theranostics).

In conclusion, surface modification is not merely an optional enhancement but an **essential engineering step** in the design of magnetic nanoparticle-based drug delivery systems. The integration of bio-inert polymers, selective ligands, and smart-release mechanisms holds tremendous promise for **personalized medicine**, where treatments can be tailored to individual patients with maximum efficacy and minimum side effects.

6. RECOMMENDATIONS

Based on the comprehensive analysis of surface modification techniques for magnetic nanoparticles (MNPs) in targeted drug delivery, the following strategic recommendations are proposed to improve design, efficiency, biocompatibility, and translational feasibility:

6.1 Adopt Hybrid Surface Engineering Approaches

- Employ **multifunctional coatings** that integrate **polymeric stability (e.g., PEG or dextran)** with **ligand-mediated targeting** to achieve both long circulation and site-specific delivery.

- Consider **layer-by-layer functionalization** to enable stimuli-responsive behavior without compromising core stability.

6.2 Prioritize Biocompatibility and Biodegradability

- Use **natural or FDA-approved biopolymers** (e.g., chitosan, alginate, gelatin) for surface modification to minimize immune reactions and facilitate safe degradation.
- Conduct **long-term toxicity and metabolism studies** in vivo to ensure safety across organ systems.

6.3 Optimize Ligand Conjugation Techniques

- Utilize **site-specific and oriented conjugation methods** (e.g., click chemistry, thiol-maleimide linking) to preserve ligand functionality and improve receptor binding.
- Standardize **ligand density control protocols** to avoid steric hindrance and aggregation.

6.4 Integrate Stimuli-Responsive Release Mechanisms

- Develop **pH-sensitive, temperature-sensitive, or enzyme-sensitive coatings** for smart release in pathological environments such as tumors or infected tissues.
- Explore the use of **external triggers** (e.g., alternating magnetic field or NIR light) in combination with surface-functionalized MNPs for remote-controlled release.

6.5 Strengthen Characterization and Quality Control

- Employ **advanced surface characterization tools** (e.g., XPS, FTIR, DLS, TEM) to monitor coating uniformity, charge, and stability.
- Establish **batch-to-batch reproducibility criteria** and validation protocols for each surface modification method.

6.6 Enhance Scalability and Cost-Effectiveness

- Focus on **scalable synthesis methods** such as microfluidics, self-assembly, and green chemistry routes that minimize hazardous solvents and allow mass production.
- Choose materials and processes that are **cost-effective and environmentally sustainable** for large-scale pharmaceutical applications.

6.7 Regulatory and Translational Readiness

- Engage early with **regulatory frameworks** (FDA, EMA) to align with safety and efficacy documentation requirements for clinical trials.
- Initiate **pilot studies in animal models** with GMP-grade MNP formulations to test in vivo biodistribution, clearance, and therapeutic effects.

6.8 Encourage Interdisciplinary Collaborations

- Foster collaboration between **material scientists, biologists, chemists, pharmacologists, and clinicians** to co-develop clinically translatable systems.
- Create shared platforms for data exchange on **toxicology, pharmacokinetics, and functionalization methods** across research institutions.

6.9 Promote Theranostic Applications

- Design surface-modified MNPs with dual or triple functionalities—**drug delivery + imaging + photothermal response**—to enable real-time diagnosis and monitoring during therapy.
- Encourage the development of **patient-specific nanocarriers** via molecular profiling and targeted ligand selection.

6.10 Public Awareness and Ethical Oversight

- Ensure that the advancement of nanomedicine remains **ethically grounded**, with transparent risk-benefit communication to patients and the public.
- Establish **bioethical oversight boards** for evaluating new nanocarriers before clinical use.

7. CONCLUSION

The surface modification of magnetic nanoparticles (MNPs) represents a cornerstone in their successful implementation for targeted drug delivery applications. Through an in-depth review and comparative analysis, this study confirms that **surface functionalization is not merely an auxiliary enhancement**, but a fundamental requirement for converting raw magnetic nanomaterials into **biocompatible, stable, and efficient theranostic platforms**.

Polymeric coatings such as PEG, dextran, and chitosan have proven critical in enhancing **colloidal stability, blood circulation time, and immune evasion**, thus enabling MNPs to remain longer in systemic circulation and accumulate at target sites more effectively. On the other hand, **ligand conjugation**, using biological molecules such as folic acid, antibodies, and peptides, has enabled **active targeting** of diseased tissues through receptor-mediated endocytosis, dramatically improving therapeutic precision and reducing off-target side effects.

Moreover, the incorporation of **inorganic shells like silica and gold** has unlocked additional capabilities such as **stimuli-responsive drug release, high drug loading, and imaging compatibility**, expanding the multifunctionality of MNPs. However, the study also identifies challenges such as reproducibility, in vivo behavior, immune responses, and scalability that need to be systematically addressed before clinical translation can be realized.

Importantly, the synthesis and surface functionalization strategies must strike a careful balance between **complexity and feasibility**—ensuring that enhancements in functionality do not compromise safety, reproducibility, or regulatory acceptance.

In conclusion, the future of precision nanomedicine lies in the **rational design of surface-modified MNPs** that integrate targeting ability, therapeutic payload delivery, imaging capability, and safety within a single nano-platform. This study not only provides a foundation for further experimental research but also offers a strategic roadmap for researchers and technologists aiming to translate magnetic nanoparticle technologies from the laboratory bench to clinical bedside.

REFERENCES

[1] Berry, C. C., & Curtis, A. S. G. (2003). Functionalisation of magnetic nanoparticles for applications in biomedicine. *Journal of Physics D: Applied Physics*, 36(13), R198.
[2] Dobson, J. (2006). Magnetic nanoparticles for drug delivery. *Drug Development Research*, 67(1), 55–60.
[3] Gupta, A. K., & Gupta, M. (2005). Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials*, 26(18), 3995–4021.
[4] Jain, T. K., Morales, M. A., Sahoo, S. K., Leslie-Pelecky, D. L., & Labhasetwar, V. (2005). Iron oxide nanoparticles for sustained delivery of anticancer agents. *Molecular Pharmaceutics*, 2(3), 194–205.
[5] Mahmoudi, M., Sant, S., Wang, B., Laurent, S., & Sen, T. (2011). Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy. *Advanced Drug Delivery Reviews*, 63(1), 24–46.
[6] Mody, V. V., Cox, A., Shah, S., Singh, A., Bevins, W., & Parihar, H. (2014). Magnetic nanoparticle drug delivery systems for targeting tumor. *Applied Nanoscience*, 4(4), 385–392.
[7] Pankhurst, Q. A., Connolly, J., Jones, S. K., & Dobson, J. (2003). Applications of magnetic nanoparticles in biomedicine. *Journal of Physics D: Applied Physics*, 36(13), R167.
[8] Sun, C., Lee, J. S., & Zhang, M. (2008). Magnetic nanoparticles in MR imaging and drug delivery. *Advanced Drug Delivery Reviews*, 60(11), 1252–1265.
[9] Xu, C., Xu, K., Gu, H., Zhong, X., Guo, Z., Chang, D., & Xu, B. (2011). Nitrilotriacetic acid-modified magnetic nanoparticles as a general agent to bind histidine-tagged proteins. *Journal of the American Chemical Society*, 126(11), 3392–3393.
[10] Yu, M. K., Park, J., & Jon, S. (2012). Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. *Theranostics*, 2(1), 3–44.